Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Single Dose Study of SA-237 in Healthy Volunteers

Next Previous
X
Search
Trial Profile

A Phase I Single Dose Study of SA-237 in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Satralizumab (Primary) ; Satralizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Sponsors Chugai Pharmaceutical

    • Most Recent Events

    • 01 May 2020 Results of populaion PK model-predicted exposure of satralizumab doses from two phase 2 clinical studies: SAkuraStar, SAkuraSky and a phase 1 satralizumab trial were presented at the 72nd Annual Meeting of the American Academy of Neurology
    • 01 May 2020 Results assessing pharmacological characteristics (pharmacokinetics and pharmacodynamics) from two clinical studies (SAkuraSky and SAkuraStar; n=104 NMOSD patients), Japanese healthy volunteers (n=72) and in rheumatoid arthritis (JapicCTI121786; n=33) patients were presented at the 72nd Annual Meeting of the American Academy of Neurology
    • 11 Sep 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top